Objective To study the effect of aerobic exercise and dietary intervention on lipid metabolism in metabolic syndrome rats, and investigate the possible mechanism mediated by peroxisome proliferator-activated receptor α (PPAR α). Methods After one-week feeding, Sprague-Dawley rats were randomly divided into blank control group (CC group) and model group which were feed in high-fat-and-salt diet for 18 weeks to establish a metabolic syndrome model. Then, the metabolic syndrome rats were randomly divided into model control group (MC), the model high-fat diet group (MHE) and the model general died exercise group (ME). ME and MHE groups were forced to run on a treadmill for twelve weeks at the same time. The weight of perirenal fat, blood free fat acid (FFA), and blood lipid were determined. The expression of PPARα mRNA in myocardium was detected by RT-PCR. Western blotting was applied to detect the protein expression of PPARα in myocardium. Results Compared with CC group, MC group showed significant increase in body weight, perirenal fat weigh, FFA, and blood lipid (P<0.05), and significant decrease in PPARα mRNA and protein expression (P<0.01) in myocardium. Compared with MC group, ME and MHE groups showed significant decrease in body weight, perirenal fat weight, triglyceride (TG), and showed significant increase in high-density lipoprotein (HDL), and the expression of PPARα mRNA and protein in myocardium (P<0.05). Compared with MHE group, ME group showed decrease in low-density lipoprotein (LDL) (P<0.05), and increase in the expression of PPARα mRNA and protein (P<0.01). Conclusion Aerobic exercise may activate the expression of PPARα, enhance the utilization of fatty acid, reduce body mass and visceral fat mass, improve the dyslipidemia and then regulate lipid metabolism in metabolic syndrome rats.
ZHANG Chong-lin
,
LIU Shao-sheng
,
XIA Zhi
,
WANG Shi-xiang
,
DING Xiao-min
,
WANG Qian-jin
,
WANG Hui
. Effect of Aerobic Exercises and Dietary Intervention on Lipid Metabolism in Rats with Metabolic Syndrome and Mechanism Medicated by Peroxisome Proliferator-Activated Receptor α[J]. Chinese Journal of Rehabilitation Theory and Practice, 2017
, 23(6)
: 662
-666
.
DOI: 10.3969/j.issn.1006-9771.2017.06.009
[1] De Sousa SMD, Norman RJP. Metabolic syndrome, diet and exercise [J]. Best Pract Res Clin Obstet Gynaecol, 2016, 37: 140-151.
[2] Berger J, Moller DE. The mechanisms of action of PPARs [J]. Annu Rev Med, 2002, 53: 409-435.
[3] Kuwahara K, Honda T, Nakagawa T, et al. Leisure-time exercise, physical activity during work and commuting, and risk of metabolic syndrome [J]. Endocrine, 2016, 53(3): 710-721.
[4] Federation ID. The IDF consensus worldwide definition of the metabolic syndrome [J]. Ožirenie i Metabolizm, 2005, 2(3): 47-49.
[5] 颜虹,徐勇勇. 医学统计学[M]. 3版. 北京:人民卫生出版社, 2015: 242.
[6] Bedford TG, Tipton CM, Wilson NC, et al. Maximum oxygen consumption of rats and its changes with various experimental procedures [J]. J Appl Physiol Respir Environ Exerc Physiol, 1979, 47(6):1278-1283.
[7] Gilde AJ, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease [J]. J Am Coll Cardiol, 2006, 48(Suppl): A25-A32.
[8] Kersten S. Integrated physiology and systems biology of PPARα [J]. Mol Metab, 2014, 3(4): 354-371.
[9] Yan Y, Wang ZB, Tang CK. PPARs mediate the regulation of energy metabolism by long- chain fatty acids [J]. Sheng Li Ke Xue Jin Zhan, 2016, 47(1): 1-6.
[10] Ibarra-Lara L, Sanchez-Aguilar M, Sanchez-Mendoza A, et al. Fenofibrate therapy restores antioxidant protection and improves myocardial insulin resistance in a rat model of metabolic syndrome and myocardial ischemia: the role of angiotensin II [J]. Molecules, 2016, 22(1): 31-48.
[11] Tsunoda F, Asztalos IB, Horvath KV, et al. Fenofibrate, HDL, and cardiovascular disease in type-2 diabetes: The DAIS trial [J]. Atherosclerosis, 2016, 247: 35-39.
[12] Song D, Chu Z, Min L, et al. Gemfibrozil not fenofibrate decreases systemic glucose level via PPARalpha [J]. Pharmazie, 2016, 71(4): 205-212.
[13] Lucero D, Miksztowicz V, Macri V, et al. Overproduction of altered VLDL in an insulin-resistance rat model: Influence of SREBP-1c and PPAR-alpha [J]. Clin Investig Arterioscler, 2015, 27 (4): 167-174.
[14] Lee TW, Bai KJ, Lee TI, et al. PPARs modulate cardiac metabolism and mitochondrial function in diabetes [J]. J Biomed Sci, 2017, 24(1): 5.
[15] 胡莲美,郑文岭,朴英杰. 过氧化物酶体增殖物激活受体的医学重要性[J]. 医学分子生物杂志, 2005, 2(2):140-142.
[16] Akiyama TE, Meinke PT, Berger JP. PPAR ligands: potential therapies for metabolic syndrome [J]. Curr Diab Rep Feb, 2005, 5(1): 45-52.
[17] Chen L, Jia Z, Yang G. PPARs and Metabolic Syndrome [J]. PPAR Res, 2014, 2014: 832606.
[18] Gross B, Pawlak M, Lefebvre P, et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD [J]. Nat Rev Endocrinol, 2017, 13(1): 36-49.
[19] Fuentes E, Guzman-Jofre L, Moore-Carrasco R, et al. Role of PPARs in inflammatory processes associated with metabolic syndrome (review) [J]. Mol Med Rep, 2013, 8(6): 1611-1616.
[20] Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation [J]. Trends Endocrinol Metab, 2012, 23(7): 351-363.
[21] Matsuo T, So R, Shimojo N, et al. Effect of aerobic exercise training followed by a low-calorie diet on metabolic syndrome risk factors in men [J]. Nutr Metab Cardiovasc Dis, 2015, 25(9): 832-838.
[22] Batatinha HA, Lima EA, Teixeira AA, et al. Association between aerobic exercise and rosiglitazone avoided the NAFLD and liver inflammation exacerbated in PPAR-alpha knockout mice [J]. J Cell Physiol, 2017, 232(5): 1008-1019.
[23] Zhang S, Liu Y, Li Q, et al. Exercise improved rat metabolism by raising PPAR-alpha [J]. Int J Sports Med, 2011, 32(8): 568-573.
[24] Santos MH, Higuchi Mde L, Tucci PJ, et al. Previous exercise training increases levels of PPAR-alpha in long-term post-myocardial infarction in rats, which is correlated with better inflammatory response [J]. Clinics (Sao Paulo), 2016, 71(3): 163-168.
[25] Campbell FM, Kozak R, Wagner A, et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase [J]. J Biol Chem, 2002, 277(6): 4098-4103.
